Skip to main content

Kintara Therapeutics Stock Forecast, Price & News

+0.05 (+3.94 %)
(As of 05/18/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume151,665 shs
Average Volume824,179 shs
Market Capitalization$42.74 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Kintara Therapeutics logo

About Kintara Therapeutics

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KTRA
Phone858 350 4364
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value($0.40) per share


Net Income$-9,130,000.00




Market Cap$42.74 million
Next Earnings Date9/20/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.83 out of 5 stars

Medical Sector

139th out of 2,050 stocks

Pharmaceutical Preparations Industry

55th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kintara Therapeutics (NASDAQ:KTRA) Frequently Asked Questions

Is Kintara Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kintara Therapeutics stock.
View analyst ratings for Kintara Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Kintara Therapeutics?

Wall Street analysts have given Kintara Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kintara Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kintara Therapeutics' next earnings date?

Kintara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 20th 2021.
View our earnings forecast for Kintara Therapeutics

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) issued its earnings results on Friday, May, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.05.
View Kintara Therapeutics' earnings history

How has Kintara Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Kintara Therapeutics' stock was trading at $0.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KTRA stock has increased by 153.8% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19

When did Kintara Therapeutics' stock split? How did Kintara Therapeutics' stock split work?

Shares of Kintara Therapeutics reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Kintara Therapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for KTRA?

2 brokers have issued 12-month price targets for Kintara Therapeutics' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Kintara Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for Kintara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Kintara Therapeutics' key executives?

Kintara Therapeutics' management team includes the following people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 68, Pay $822.5k)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 71, Pay $200k)
  • Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc, CFO & Sec. (Age 54, Pay $366k)
  • Mr. Jeffrey A. Bacha, Founder (Age 53)
  • Mr. Greg A. Johnson, Acting Head of Operations
  • Mr. John Liatos, Sr. VP of Bus. Devel. & Director (Age 53)

Who are some of Kintara Therapeutics' key competitors?

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), (DMPI), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

What is Kintara Therapeutics' stock symbol?

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

Who are Kintara Therapeutics' major shareholders?

Kintara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (2.79%), swisspartners Ltd. (0.85%), Geode Capital Management LLC (0.47%), Citadel Advisors LLC (0.24%), Northern Trust Corp (0.14%) and Envestnet Asset Management Inc. (0.05%).
View institutional ownership trends for Kintara Therapeutics

Which institutional investors are buying Kintara Therapeutics stock?

KTRA stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, swisspartners Ltd., Geode Capital Management LLC, Citadel Advisors LLC, Northern Trust Corp, and Envestnet Asset Management Inc..
View insider buying and selling activity for Kintara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Kintara Therapeutics?

Shares of KTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kintara Therapeutics' stock price today?

One share of KTRA stock can currently be purchased for approximately $1.32.

How much money does Kintara Therapeutics make?

Kintara Therapeutics has a market capitalization of $42.74 million. The company earns $-9,130,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does Kintara Therapeutics have?

Kintara Therapeutics employs 4 workers across the globe.

What is Kintara Therapeutics' official website?

The official website for Kintara Therapeutics is

Where are Kintara Therapeutics' headquarters?

Kintara Therapeutics is headquartered at 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130.

How can I contact Kintara Therapeutics?

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858 350 4364 or via email at [email protected]

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.